While clinical trials of small molecule CSF1R inhibitors and CSF1/CSF1R antibodies have been conducted in various types of cancer, a single reagent, PLX3397, has been clinically approved only for tenosynovial giant cell tumor (TGCT) (13, 37). The gene discussed is CSF1R; the disease is cancer.